Navigation Links
Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee

MEMPHIS, Tenn., April 22 /PRNewswire-FirstCall/ -- As evidence of its drive to return knee pain sufferers to a lifetime of physical activity, Smith & Nephew ( SNN, LSE: SN) Orthopaedics Division today announces the results of unprecedented testing on its VERILAST technology for knee replacement implants. After simulating 30 years of physical activity on the company's LEGION™ knee replacement, VERILAST technology produced an 81-percent reduction* in wear, the leading cause of knee replacement failure.

The Food and Drug Administration (FDA) has reviewed the results and Smith & Nephew received 510k clearance for claims related to VERILAST technology's ability to "provide wear performance sufficient for 30 years of actual use under typical conditions." The consensus of scientific literature is that knee implants are expected to last 10 to 15 years.

"Physically active patients want to end their knee pain for good," said Joseph M. DeVivo, president of Smith & Nephew Orthopaedics. "We're working to make knee implants that last a lifetime—that's our goal, and we've validated VERILAST technology out to 30 years for a market that views 10 to 15 years as the gold standard. This is not an incremental improvement; it's a generational leap forward for active patients.

"Every orthopaedic device company has focused for years, if not decades, on developing the best possible bearing surfaces for improving the performance and longevity of knee implants," said Scott Elliott, senior vice president, global knee franchise, for Smith & Nephew Orthopaedics. "To reduce wear in knee replacements, companies have all created their own formulas for the dense plastic component (highly cross-linked polyethylene, or XLPE) used on the tibial side of a knee implant. And all companies, including Smith & Nephew, have reported progress on this front. But there are two bearing surfaces in a knee, and only one company has been successful in improving the other side of the joint—the metal femoral component.  

"Smith & Nephew is the only company in the world to commercialize an advanced bearing surface for the femoral component of a knee replacement. OXINIUM™ oxidized zirconium is a proprietary material which has been used in more than 200,000 knee procedures and is proven to reduce wear. It is also the only hypoallergenic metal bearing surface since it contains no detectable amounts of nickel, the element commonly associated with metal allergies.

"VERILAST technology is the unique combination of our exclusive OXINIUM material and the most advanced XLPE on the market. Together, they yield virtually indiscernible wear. After performing wear simulator testing of the knee replacements over three continuous years, we have confirmed that this Smith & Nephew knee replacement made with VERILAST technology, under normal circumstances, is expected to last for 30 years."

Typically, if a knee replacement fails due to wear, the patient will undergo a "revision" surgery in which the original components will be replaced with more invasive, more expensive ones. While there may be some decrease in implant performance, the primary costs of revision surgery are in its risk of infection and bone loss for the patient and the procedure's cost for the healthcare system.

"If we're successful in our drive to make knee replacements that last a lifetime, that could mean significant cost savings to the healthcare system," said DeVivo. "And patients may avoid the pain and the downtime associated with revision surgery."

Failure due to wear is one of several known reasons for revision surgery.  VERILAST technology may significantly reduce the risk of failure for patients who would have been revised due to wear.

About VERILAST Technology

VERILAST technology is the combination of two advanced bearing surface technologies: Smith & Nephew's patented metal alloy OXINIUM oxidized zirconium, used on the femoral side of the joint, and highly cross-linked polyethylene (plastic), implanted on the tibial side. OXINIUM material has been in use in knee replacements for more than a decade, but was only recently coupled with highly cross-linked polyethylene components. OXINIUM is a metal alloy that undergoes a proprietary heating process, transforming its surface into a hard, smooth ceramic that is 4,900 times more resistant to scratching than traditional materials. It is 20-percent lighter than cobalt chromium, the metal used in conventional knee replacements, and because it doesn't contain detectable amounts of nickel like cobalt chromium does, it is considered hypoallergenic and safe for patients with metal allergies.

Smith & Nephew's primary knee replacement systems, the LEGION and GENESIS™ II knee implants, are currently available with VERILAST technology.

*As compared to wear simulator data seen for a traditional bearing couple for an estimated five years

About Us

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management.  Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives.  The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust.  The Company operates in 32 countries around the world.  Annual sales in 2009 were nearly $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995.  In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline.  These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements.  Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.  Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof.  All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing.  Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

™Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

SOURCE Smith & Nephew
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
2. SpineSmith to Present at the 5th Annual Stem Cell Summit
3. SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement
4. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
5. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
6. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
7. GlaxoSmithKline Completes Acquisition of Stiefel
8. Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair
9. Vasogen Appoints Dr. Eldon Smith Chairman
10. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
11. American Geographical Society awards honor Henson, Smith on April 15 at UD
Post Your Comments:
(Date:2/17/2017)... , Feb. 17, 2017  If only one ... had a mutation-conferring resistance to chemotherapy, thousands of ... research has focused on finding these mutations in ... from circulating tumor DNA in blood — to ... therapeutics. Unfortunately, however, detecting these genetic ...
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
Breaking Biology News(10 mins):